<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1850</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>101</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-12-18</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-11</thesisDateAccepted>
    <title language="eng">Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma</title>
    <abstract language="eng">Glioblastoma represents a challenge in oncology, characterized by its aggressive nature and resistance to conventional therapies. This thesis conducts a comprehensive examination of Glioblastoma, with a primary focus on advancing therapeutic strategies through precision medicine and sophisticated drug delivery mechanisms. The inquiry starts with an exhaustive analysis of the intricate blood-brain barrier, a vital neurovascular interface critical for understanding drug delivery complexities to the central nervous system. Subsequently, the study delves into Glioblastoma, elucidating its etiological foundations, molecular intricacies, clinical presentations, and existing treatment paradigms.&#13;
The core of this research centers on the exploration of state-of-the-art targeted therapies, encompassing molecular-level targeting, immunotherapeutic modalities, and synergistic therapeutic approaches. It dissects a range of strategies aimed at enhancing drug delivery, including chemical disruption techniques, innovative delivery methodologies, and bioengineered approaches.&#13;
Furthermore, it underscores the transformative potential of nanotechnology, emphasizing nanocarriers as precision tools poised to revolutionize GBM therapy.&#13;
The literature review is conducted meticulously, drawing from renowned databases like PubMed, NCBI, NIH/National Cancer Institute, JSTOR, and BioMed Central. Additionally, reputable national and international health institute websites, along with carefully selected books from the campus library, contribute to the diverse and robust foundation of credible information.&#13;
The discussion segment dissects the challenges inherent in GBM targeted treatment, underscores the burgeoning domain of precision medicine, highlights the paradigm-shifting role of theranostics,&#13;
and outlines a roadmap for future prospects in this intricate landscape.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18504</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Fatma Belkhodja</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1850/Belkhodja.BSc.thesis.pdf</file>
  </doc>
  <doc>
    <id>1814</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>99</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-10-03</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-15</thesisDateAccepted>
    <title language="eng">The use of biocatalysis in the diagnosis and treatment of colorectal cancer (CRC)</title>
    <abstract language="eng">Colorectal cancer is a significant global health burden. Early-stage colorectal cancer is asymptomatic, which, coupled with the fact that later stages of CRC have a very low prognosis, and that current methods of diagnosis and treatment significantly impact the patient, exploring alternate ways to diagnose and treat CRC is vital.&#13;
Biocatalysis is the use of naturally found catalysts such as nanozymes and enzymes in order to catalyze reactions. Due to their characteristics and uses, biocatalysts are seen as promising alternatives to current methods of CRC diagnosis and therapy.&#13;
This research-based bachelor thesis aims to summarize and analyze current traditional and biocatalytic methods that exist to diagnose and treat CRC, in order to seek the potential of biocatalysis in this field, as well as discuss its current state and its future in comparison to currently implemented methods. It provides an extensive overview of traditional and biocatalytic approaches to diagnosis and therapy, considering important factors such as efficacy, sensitivity, selectivity, cost, and safety.&#13;
The thesis also delves into the use of biocatalysis for important points such as the early diagnosis of CRC, and the challenges faced during development, regulation, and monetary concerns. Through careful analysis of the strengths and limitations of techniques in the field, as well as personal opinions on the future of research, conclusions on given hypotheses regarding biocatalysis in CRC diagnosis and therapies were presented and included strong support for the unquestionable potential of biocatalysis use in cancer healthcare, while highlighting possibilities to tap into that potential by scrutinizing their equally as unquestionable current limitations.&#13;
Overall, this thesis aspires to contribute, on however minuscule a scale, towards the advancement of CRC diagnosis and therapy approaches, with the ambition of improving patient care and prognosis, as well as quality of life for those struggling or who will struggle in the future with the disease, together with their kin who are profoundly affected as well.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18147</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Basil Mazen Hammoudeh</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Colorectal cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Biocatalysis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Enzymes</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Diagnosis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Therapy</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1814/BasilHammoudeh_Thesis_FINAL_SIGNED.pdf</file>
  </doc>
  <doc>
    <id>1820</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>deu</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>masterthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-10-25</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-05</thesisDateAccepted>
    <title language="deu">Betriebliches Eingliederungsmanagement (BEM) in der Stadtverwaltung Halle  (Saale) im Kontext psychischer Erkrankungen</title>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Bestimmungen des deutschen Urheberrechts</licence>
    <author>Janine Walter</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
  </doc>
  <doc>
    <id>1796</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>masterthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-08-28</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-08-21</thesisDateAccepted>
    <title language="eng">The Use of Pig insulin and Grafts in the treatment of Human Diabetes</title>
    <abstract language="eng">Biological resources are entities of natural origin with sources from either plants or animals that render a broad number of services to mankind. Purified pig insulin, pancreas, islet, and beta cells are biological resources synthesized, extracted, and isolated from pigs to provide medical services like treating human diabetes. &#13;
The observed methodology was obtained by systematically reviewing and comparing other similar scientific studies to determine the challenges and risks associated with using pig grafts (islet, pancreas, beta cells) for the treatment of type 1 diabetes (T1D), the optimal pig age for extracting graft for treatment of diabetes, differences between human and pig insulin, and the clinical trials and adoption pig insulin and graft therapies for type 1 diabetes treatment.&#13;
Xenotransplantation of pig grafts has successfully restored normoglycemia in a Type 1 diabetes patient for about 9.5 years, thus potentially being an alternative therapy to human islet allotransplantation. However, the clinical adoption of using &#13;
pig grafts for diabetes treatment is hindered by the unavailability of T1D volunteers to be used for clinical trials because of risks like zoonosis, loss of body weight, immunosuppression, and death of the transplanted pig implant.&#13;
Xenotransplantation of pig grafts to T1D can be clinically accepted through advanced practices like Genetic modifications of the pig, encapsulating the pig grafts before transplantation, and co-transplantation of the pig grafts with Mesenchymal Stem Cell (MSCs) and/or Sertoli cells (SCs). The clinical adoption of pig grafts for T1D treatment will mitigate the problem of limited islet/pancreas &#13;
donor sources encountered in allotransplantation, hence more research and studies are needed for this milestone to be accomplished.</abstract>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Somtoo Dominic Okolie</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
  </doc>
  <doc>
    <id>1673</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>80</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-02-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-12-27</thesisDateAccepted>
    <title language="eng">Evaluating the potential of mRNA vaccines for human rabies</title>
    <abstract language="eng">To this date, rabies is still one of the most fatal diseases worldwide and generates at least 59,000 deaths per year. Although current vaccines are safe and effective, RNA technology proposes improved vaccines that are potentially able to facilitate eradication of rabies until 2030. In this review, RNA vaccine candidates are evaluated for their potential to be effective against rabies and to be implemented in immunization programs. To understand the relevance of disease prevention, rabies virus and its function in the body is clarified. RNA technology is explained to comprehend its mode of action in the human immune system and its potential to be a vaccine platform. Comparison to existing vaccines showed advantages in several characteristics that are relevant for vaccine approval. RNA vaccines scored better in efficacy, stability, production, and dosing, but there is still room for improvements in terms of safety and tolerability. Theoretical potential is proven, but practical translation of RNA vaccines into clinical candidates requires more attention, as safety and tolerability are the leading limiting factor for approval of any new drug or vaccine. Producing a safe, stable and effective RNA vaccine does not necessarily ensure less rabies deaths, because rabies control strategies heavily rely on proper funding and availability in these rabies endemic region. Nonetheless, RNA vaccine technology offers potential solutions for the elimination of rabies.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16737</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Bestimmungen des deutschen Urheberrechts</licence>
    <author>Ole Waller</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1673/Bachelorthesis_OWaller_25337.pdf</file>
  </doc>
  <doc>
    <id>1728</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>deu</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>91</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-04-17</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-03-13</thesisDateAccepted>
    <title language="deu">In vitro Fleisch als Alternative zu konventionellem Fleisch</title>
    <abstract language="deu">Durch die wachsende Weltbevölkerung kommt es zu einem steigenden Fleischkonsum, der mit unerwünschten Folgen für die Umwelt und die Gesundheit sowie das Wohlergehen der Tiere einhergeht. Durch die konventionelle Fleischproduktion entstehen hohe Treibhausgasmengen sowie ein hoher Wasser- und Landverbrauch. Der Verzehr von verarbeitetem und rotem Fleisch erhöht das Krebsrisiko und begünstigt die Entstehung von Herz-Kreislauf-Erkrankungen, Diabetes und Bluthochdruck. Bei der Aufzucht der Tiere werden zur Vermeidung von bakteriellen Infektionen Antibiotika eingesetzt, die Auswirkungen auf die menschliche Gesundheit haben können. Das Wohlergehen der Tiere ist aufgrund des hohen Stressniveaus durch schlechte Haltungsbedingungen nicht gegeben. Zur Verbesserung der Risiken durch konventionell hergestelltes Fleisch werden Alternativen erforscht. Ziel ist es die sensorischen und geschmacklichen Komponenten des konventionellen Fleisches nachzuahmen und eine Verbesserung der Gesundheit, Umwelt und das Wohlergehen der Tiere zu erzeugen. Neben den auf dem Markt erhältlichen pflanzlichen Fleischprodukten, deren Sensorik noch nicht ausgereift ist, befasst sich die Forschung mit der Entwicklung von in vitro Fleisch sowie Fleisch aus dem 3D-Drucker. Die Herstellung von in vitro Fleisch nach dem Tissue Engineering Verfahren entstammt der Stammzellenforschung und Gewebezüchtung. Stammzellen eines Tieres werden entnommen und mithilfe eines Nährmediums, einem Gerüst und einem Bioreaktor zu Geweben kultiviert, die dem konventionellem Fleisch ähneln. Durch das Hinzufügen von Komponenten wie z.B. Vitamine oder gesunde Fette kann die Sensorik und der Geschmack des in vitro Fleisches verbessert werden. Der Verbrauch von Land und die Umweltbelastung durch Treibhausgase sind geringer als bei der konventionellen Fleischherstellung. Dennoch stellen sich bei der in vitro Fleischproduktion noch offene Herausforderungen in Bezug auf die Umwelt, Gesundheit und Sensorik. Damit in vitro Fleisch auf dem Markt zugelassen werden kann, muss die Sicherheit des Produktes gewährleistet sein. Die Verbraucherakzeptanz ist eingeschränkt, da wenig Informationen und Studien zu den Auswirkungen auf die Umwelt und Gesundheit vorliegen, die auf bewiesenen Ergebnissen beruhen. Weitere Forschungen sind nötig, um die Akzeptanz zu erhöhen und die Hürden zu überwinden. Die vorliegende Arbeit soll einen Überblick über den aktuellen Forschungsstand von in vitro Fleisch als Alternative zu konventionellem Fleisch geben.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-17287</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Sabrina Stuckmann</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1728/Stuckmann_Bachelorarbeit.pdf</file>
  </doc>
  <doc>
    <id>1696</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-03-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">A Structured Classification and Evaluation of Current and Future Treatments for Systemic Lupus Erythematosus</title>
    <abstract language="eng">Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease that has a variety of manifestations and is therefore difficult to find a treatment for. Several advances have occurred in the field of SLE drug discovery, especially since the publishing of the first Genome Wide-Associated Studies in 2005. More than one hundred loci were found to be involved in the disease. Subsequently, the treatments were aimed towards tackling the pathways that were found after the uses of modern genetic techniques. Historically, the FDA approved only two drugs for treatment until the approval of Belimumab in 2011. Ten years later, two more drugs were approved in the same year, with few more drugs expected to receive approval in the near future. This study aims to evaluate the efficacy of these future drugs in addition to the ones considered to be milestones in the treatment of SLE, finding Anifrolumab to be the most promising drug currently on the market for treatment of moderate to severe SLE and Obinutuzumab to be the drug to watch.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16960</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Ahmed Abdelazim</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1696/Abdelazim_Lupus.pdf</file>
  </doc>
  <doc>
    <id>1692</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-02-27</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-02-14</thesisDateAccepted>
    <title language="eng">MESENCHYMAL STEM CELLS (MSC) IN BREAST CANCER TREATMENT: ADVANTAGES AND CHALLENGES OVER TRADITIONAL THERAPIES</title>
    <abstract language="eng">Breast cancer is one of the most prevalent and deadly malignancies in women globally, due to its aggressive behavior and poor response to traditional treatments. Despite the significant improvements in understanding of tumor therapies, efforts to treat patients with advanced cancer are still hampered by the size and heterogeneity of the tumor burden and the development of drug resistance. Therefore, the need for novel therapeutic strategies is essential.&#13;
Mesenchymal stem cells (MSCs) have been studied for a long time with encouraging results in the treatment of metastatic cancers, including breast cancer. The discovery of MSCs' therapeutic abilities to inhibit the growth of cancer, cause cell death, and trigger immune responses served as a catalyst for the development of bioengineered MSCs. The use of MSCs in cell therapy is the subject of numerous investigations now. &#13;
This thesis aimed to summarize the current knowledge on traditional breast cancer treatments and compare them to novel approaches based on MSCs usage. To this end, scientific publications retrieved from databases such as PubMed were selected considering specific inclusion/exclusion criteria and were extensively analyzed. Results obtained underline the potential applications of MSCs for breast cancer treatment, such as using MSCs as carriers of oncolytic viruses, suicide genes, and anticancer medicines to malignancies. Furthermore, challenges and limitations of several MSCs based treatments and MSCs control were evaluated and discussed based on ongoing clinical trials.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16927</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Olga Chentsova</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>MSC</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Mesenchymal stem cells</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Traditional cancer therapies breast cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>BC</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Treatment</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1692/Chentsova_MSCs.pdf</file>
  </doc>
</export-example>
